-

Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice

FOSTER CITY, Calif. & WASHINGTON--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and the Human Rights Campaign (HRC), the nation’s largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization, today announced that Gilead will provide a $3.2 million grant over two years to support communities disproportionately impacted by the HIV epidemic in the United States, particularly communities of color. Gilead will directly fund the efforts of the HRC Foundation – HRC’s educational arm – aimed at ending the HIV epidemic, as well as fund the organization’s Transgender Justice Initiative.

This innovative initiative builds on core strengths of each organization, including Gilead’s long-standing efforts to address healthcare disparities and HRC’s leadership in advancing justice for LGBTQ+ communities for more than 40 years. It also builds on HRC’s commitment to programmatic work that actively challenges systems, laws and policies that disproportionately disadvantage LGBTQ+ people of color. Through this initiative, HRC will launch a public education campaign to change the narrative by focusing on dismantling stigma and discrimination while developing and advancing an inclusive public policy that addresses non-discrimination measures and healthcare disparities among LGBTQ+ communities.

“Too often, institutional racism and anti-LGBTQ+ bias have been barriers to comprehensive HIV prevention and treatment strategies,” said Alphonso David, President of the Human Rights Campaign. “This grant will allow the Human Rights Campaign to work directly with community partners, Historically Black Colleges and Universities, and youth serving professionals – especially those in Black and Latinx communities in the South and around the country – to increase awareness of HIV treatment and prevention options in order to reduce health disparities, and combat the discrimination and stigma that too often leads to fatal violence against transgender women of color.”

“Gilead is committed to promoting social justice and racial equity for the patients and communities we serve, as well as for our own employees,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “The grant to HRC builds on our commitment to advance equity in healthcare, particularly in Black communities and other communities of color that are disproportionately affected by HIV and other diseases.”

Stigma, homophobia and transphobia, racism, and lack of access to appropriate healthcare services are barriers to comprehensive HIV prevention and care. This particularly impacts the 1 in 4 Latino gay and bisexual cisgender men and 1 in 2 Black gay and bisexual cisgender men who will be diagnosed with HIV in their lifetime. The funding from Gilead will enable HRC to work directly with these communities in the Southern U.S. and around the country, with partners including Us Helping Us in Washington, D.C. and Prince George’s County, Maryland; Brotherhood Incorporated in New Orleans; TruEvolution in Riverside, California; Arianna’s Center in Miami and San Juan, Puerto Rico; Community Health PIER in Greenville, Mississippi; and BU Wellness Network in Indianapolis. In addition, through this work, HRC will partner with more than 30 Historically Black Colleges and Universities to supplement their efforts in providing HIV prevention education and resources to students. The funding will also support HRC’s Transgender Justice Initiative, which seeks to address the urgent needs of the transgender community, with specific attention to individuals deeply impacted by racism, sexism and transphobia.

HRC will host a virtual summit on February 23 featuring Alphonso David, HRC President and Shanell McGoy, Director, Public Affairs at Gilead, as well as advocates and community-based organization leaders, to discuss the efforts to end the HIV/AIDS epidemic in the U.S.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more than 30 years, Gilead has been a leading innovator in the field of HIV.

Gilead’s social justice work includes a number of initiatives aimed at promoting equity, particularly healthcare equity, for individuals in underserved communities. The company has committed more than $100 million over 10 years through the Gilead COMPASS Initiative® to community organizations in the Southern United States working to combat HIV/AIDS and in 2019 started the TRANScend® Community Impact Fund to support organizations committed to improving the safety, health and wellness of the transgender community. In 2020, Gilead launched the Racial Equity Community Impact Fund, which is providing $10 million in funding to 20 organizations working to tackle racial inequities affecting Black communities across the United States.

About the Human Rights Campaign Foundation

The Human Rights Campaign Foundation is the educational arm of America's largest civil rights organization working to achieve equality for lesbian, gay, bisexual, transgender and queer people. Through 11 programs and initiatives, we seek to make transformational change in the everyday lives of LGBTQ people, with a clear focus on multiply marginalized people. We have transformed the landscape for more than 15 million workers, 10 million elementary school students, 600,000 clients in the adoption and foster care system, and so much more. We work each day to shed light on injustice and deepen the public’s understanding. We provide direct consultation and technical assistance to institutions and communities, driving the advancement of inclusive policies and practices. We build the capacity of future leaders and allies through fellowship and training programs. And, with the firm belief that we are stronger working together, we forge partnerships with advocates in the U.S. and around the globe to increase our impact and shape the future of our work.

Contacts

Gilead Contact:
Chris Ridley, Media
(650) 235-2220

HRC Contact:
Elizabeth Bibi, Media
(914) 874-6865

Gilead Sciences, Inc. Logo
Gilead Sciences, Inc. Logo

Gilead Sciences, Inc.

NASDAQ:GILD

Release Versions

Contacts

Gilead Contact:
Chris Ridley, Media
(650) 235-2220

HRC Contact:
Elizabeth Bibi, Media
(914) 874-6865

More News From Gilead Sciences, Inc.

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the Gilead Foundation, supports organizations addressing food insecurity in California, North Carolina, N...

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people livin...

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to multi-tablet regimens. Gilead plans to file th...
Back to Newsroom